Appointment of executive director
Filed with HKEX · Stock code 2877 · · 2 pages · English
Summary by 6ix AI
China Shineway Pharmaceutical Group Limited has announced the appointment of Ms. Kang Limin as an executive director, effective from a future date. Ms. Kang has extensive experience in finance and corporate management, currently serving as the financial director of a subsidiary of the Company. Her appointment is for a term of two years, with a specified remuneration and eligibility for performance-related bonuses. The Board welcomes Ms. Kang to the Company and confirms there are no other matters to disclose regarding her appointment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
China Shineway Pharmaceutical Group Limited on 6ix
Earlier from China Shineway Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Retirement of executive director and change of composition of board committees
- List of Directors and their Role and Function
- Notification Letter to Non-registered Shareholders - Notification of Publication of 2026 Interim Report
- Notification Letter to Registered Shareholders - Notification of Publication of 2026 Interim Report
Later from China Shineway Pharmaceutical
All China Shineway Pharmaceutical news releasesFollow China Shineway Pharmaceutical into a list and get an email when it puts out news.
Follow China Shineway Pharmaceutical